Food and Drug Administration, Health and Human Services (HHS).
The Food and Drug Administration (FDA or Agency) is announcing the withdrawal of a final guidance for industry entitled “Investigational COVID-19 Convalescent Plasma,” which was issued in April 2020 and updated in May 2020. FDA is withdrawing the guidance because the Agency is issuing a new guidance for industry of the same title.
The withdrawal is applicable September 21, 2020.
Start Further Info
FOR FURTHER INFORMATION CONTACT:
Shruti Modi, Center for Biologics Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 71, Rm. 7301, Silver Spring, MD 20993-0002, 240-402-7911.
End Further Info
Start Supplemental Information
FDA is withdrawing the guidance for industry entitled “Investigational COVID-19 Convalescent Plasma” (May 2020 guidance) dated April 2020 and updated May 2020. The availability of this guidance was announced in the Federal Register of May 26, 2020, (85 FR 31513) and was posted on FDA's website on May 1, 2020.
On August 23, 2020, the Agency issued an emergency use authorization (EUA) (available at: https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization#coviddrugs) for COVID-19 convalescent plasma for the Start Printed Page 59321treatment of hospitalized patients with COVID-19. Given the issuance of this EUA, FDA is issuing a new guidance of the same title that provides recommendations and additional information related to the EUA for the use of COVID-19 convalescent plasma to treat hospitalized patients with COVID-19. The new guidance supersedes the May 2020 guidance. Elsewhere in this issue of the Federal Register, FDA is announcing the availability of the new guidance.
End Supplemental Information
Dated: September 16, 2020.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2020-20801 Filed 9-18-20; 8:45 am]
BILLING CODE 4164-01-P